As promising clinical trial data emerges for KRAS G12C inhibitors and with strong chances of receiving FDA approval this year, the once undruggable RAS family of proteins no longer seem impossible to be cracked. This has undoubtedly resulted in great momentum in the field of oncology to develop RAS targeted therapies that safely, effectively and selectively drug all RAS driven cancers beyond those caused by G12C mutation.
The 3rd Annual RAS Targeted Drug Development Summit is returning once again this September to reunite the biggest community of thought leaders and experts in Oncology, Cancer Therapeutics and Clinical Development to discuss robust monotherapies or combination strategies capable of specifically targeting different RAS-mutant cancer cells with less toxicity to enhance the impact of RAS therapies against all RAS driven cancers beyond lung.
Via the latest preclinical, translational and clinical development data-driven case studies from academic and industry pioneers, the 3rd RAS Targeted Drug Development Summit is your only comprehensive roadmap to addressing unique challenges and future directions of finally drugging all RAS mutations and associated targets with novel modalities and next generation combination therapies.
Incorporating tracks taking a deep dive into accelerating emerging modalities, validating robust combination strategies and advancing clinical development, this is your opportunity to gain extensive strategic and scientific information enabling you to solve the exact challenges you’re encountering to support development of safe and effective next generation RAS targeted therapies.
Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate!
2 Day Pass - Conference Only - Industry Pricing: USD 2399.00,
3 Day Pass - Conference + Workshop Day or Focus Day - Industry Pricing: USD 3498.00,
2 Day Pass - Conference Only - Academic Pricing: USD 2099.00,
3 Day Pass - Conference + Workshop Day or Focus Day - Academic Pricing: USD 2948.00,
2 Day Pass - Conference Only - Standard Pricing: USD 2899.00,
3 Day Pass - Conference + Workshop Day or Focus Day - Standard Pricing: USD 4198.00
Speakers: Gregory Friberg, Vice President Global Development and Oncology Therapeutic Area Head, Amgen, Susan Yang, Adagrasib Medical Lead, Mirati Therapeutics, Mollie Leoni, Vice President, Clinical Development, Kura Oncology, Marco Hofmann, Scientific Director and Group Leader, Boehringer Ingelheim, Mary Smith, Chief Development Officer, SpringWorks Therapeutics, Steve Kelsey, President R&D, Revolution Medicines, Marie Evangelista, Principal Scientist and Project Team Lead, Discovery Oncology, Genentech, Amotz Shemi, Chief Executive Officer, Silenseed, Iris Alroy, Vice President R&D, Anima Biotech, Anthony Partridge, Senior Principal Scientist, Merck Sharp and Dohme, Armon Sharei, Chief Scientific Officer, SQZ Biotechnologies, Karin Jooss, Head of R&D, Gritston, Jonathan Pachter, Chief Scientific Officer, Verastem Oncology, Maha Maglinao, Life Sciences and Healthcare Management Consultant, Moderna, Benedict Cross, Chief Technology Officer, PhoreMost Ltd, Charly Chahwan, Chief Scientific Officer, SyntheX, Rachel Bond, Research Scientist, SyntheX, Martin Treder, Chief Scientific Officer, Arjuna Therapeutics, Partha Das, Medical Director and US Medical Affairs Lead, Oncology, Amgen, Andrei Golosov, Senior Expert II Data Science, Novartis Institutes for BioMedical Research, Namratha Sastry, Manager Medical Affairs, Biodesix, Jan Smith, Senior Vice President, Head of Biology, Revolution Medicines, Lauren Monovich, Director, Novartis Institutes for BioMedical Research, Shuhui Lim, Senior Scientist, MSD, Sandra Wiley, Senior Medical Scientist, MEI Pharma, Inc, Raffaele Baffa, Chief Medical Officer, Ziopharm Oncology, Lusong Luo, Senior Vice President, External Innovation BeiGene, Bob Nichols, Project Team Lead, RMC-6291, Revolution Medicines, Darryl McConnell, Senior Vice President and Head Research Site Austria, Boehringer Ingelheim RCV, Matt Robers, Senior Research Scientist, Promega, Mori Mohseni, Associate Director, Bristol Myers Squibb, Andrea Wang-Gillam, Chief Medical Officer, Jacobio Pharma, Tauseef Butt, Chief Executive Officer, Progenra, Steven Fruchtman, President and CEO, Onconova Therapeutics, Andrew Koustenis, Global Program Leader, Verastem Oncology, Atli Thorarensen, Research Fellow, Pfizer, Juswinder Singh, Founder and Chief Scientific Officer, Ankaa Therapeutics, Jurgen Moll, Head of Molecular Oncology, Sanofi, Frank McCormick, Professor, Leader NCI Ras Initiative, University of California, San Francisco and Frederick National Laboratory for Cancer Research/Leidos Biomedical Research, Inc., Jessie Yanxiang, Guo Associate Professor, Rutgers Cancer Institute of New Jersey, Mariano Barbacid, AXA-CNIO Professor of Molecular Oncologym, Spanish National Cancer Research Center (CNIO), Terri Conneran, Founder and Advocate, KRASKickers.org, Andrea Gross, Assistant Research Physician, Pediatric Oncology Branch, National Cancer Institute, Michael Kim, Assistant Professor, UT MD Anderson Cancer Center, Ryan Corcoran, Associate Professor of Medicine, Harvard Medical School, Silve Vicent, Associate Professor, Center for Applied Medical Research (CIMA-University of Navarra), Ken Westover, Associate Professor of Biochemistry and Radiation Oncology, UT Southwestern Medical Center, Nir London, Senior Scientist and Assistant Professor, The Weizmann Institute of Science, Petros Grivas, Associate Professor, University of Washington, Fred Hutch, Seattle Cancer Care Alliance, Vamsidhar Velcheti, Associate Professor, Department of Medicine at NYU Grossman School of Medicine, Alessio Lodola, Associate Professor of Medicinal Chemistry, Dept. of Food and Drug, University of Parma, Eric Haura, Associate Center Director for Clinical Science, H. Lee Moffitt Cancer Center, Shohei Koide, Professor, Perlmutter Cancer Center at NYU Langone Health, and Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, Tetsuya Mitsudomi, Professor and Senior Staff, Kindai University Faculty of Medicine, Dhirendra Simanshu, Team Lead, RAS Initiative Frederick National Laboratory for Cancer Research, James DeGregori, Professor, Dept of Biochemistry and Molecular Genetics; Deputy Director, University of Colorado Cancer Center, University of Colorado Anschutz Medical Center, Marielle Yohe, Tenure Track Investigator, National Cancer Institute, Rene Bernards, Professor of Molecular Carcinogenesis, Netherlands Cancer Institute, Julian Downward, Senior Group Leader and Associate Research Director, Francis Crick Institute, Stefano Forli, Associate Professor, Scripps Research, Terry Rabbitts, Professor of Molecular Immunology, Institute of Cancer Research London, Wenshe Ray, Liu Gradipore Chair and Professor in Chemistry, Texas A&M University, Bob Li, Medical Oncologist, Co-Director, Thoracic Liquid Biopsy Program, Memorial Sloan Kettering Cancer Center, Kathryn C. Arbour, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, Matthew Bogyo, Professor, Stanford University, Wouter Van Geffen, Consultant Respiratory Physician, Medical Center Leeuwarden, Sandra Misale, Research Associate, Memorial Sloan Kettering Cancer Center